Orgenesis
ORGS
Market cap $10M

2.10 USD

-1.14

35.19%

Updated Oct 18, 3:30 PM EDT

1 day

-35.19%

5 days

-43.09%

1 month

-61.25%

3 months

-70.00%

6 months

-58.98%

Year to date

-57.32%

1 year

-78.10%

5 years

-94.52%

About: Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.

Employees: 146

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

12% more funds holding

Funds holding: 17 [Q1] → 19 (+2) [Q2]

1.33% less ownership

Funds ownership: 4.62% [Q1] → 3.29% (-1.33%) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

28% less capital invested

Capital invested by funds: $1.3M [Q1] → $932K (-$365K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ORGS.

See Analyst Rankings

Financial journalist opinion

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patients and 6% in pediatric patients in a real-world study

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint venture

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Orgenesis Provides Business Update for the First Quarter of 2024

Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera

Orgenesis Provides Business Update for the First Quarter of 2024

Orgenesis Provides Year End Business Update

M ajor transformation underway commencing with recent acquisition reasserting full ownership and control over Octomera

Orgenesis Provides Year End Business Update

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis' therapeutic programs and its suite of product development and GMP cell processing services. The collaboration's goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe. The conference, renowned for gathering leading professionals to advance the manufacturing and quality control of biological and genetic therapies, will take place in Barcelona from March 19th to 21st, 2024.

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes

GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that the Company has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project focused on manufacturing, loading, analytical methods and quality control of therapeutic exosomes. Consortium members include: Orgenesis, Cilyx, CMMI, convExYO, EXO Biologics, ExoXpert, Genflow Biosciences, LiveDrop, ULB, UMONS and Xomexbio. This grant is the second such project awarded to an Orgenesis consortium by the Walloon Government partnership, ATMP-Partenariat d'Innovation Technologique (ATMP-PIT), in collaboration with BioWin, the health cluster of Wallonia, and the Public service of Wallonia.

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes

Orgenesis Inc. Announces $2.3 Million Private Placement

GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into a definitive securities purchase agreement with certain accredited investors for the sale of 2,272,719 shares of the Company's common stock, warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of common stock at an exercise price of $2.00 per share in a private placement at a purchase price of $1.03 per share and associated warrants. The warrants are exercisable immediately and expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $2.3 million before deducting related offering expenses. The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.

Orgenesis Inc. Announces $2.3 Million Private Placement

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing

GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company's consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM). The consortium members include: Orgenesis Services Belgium, Université catholique de Louvain (UCLouvain) / TRusted AI Labs (TRAIL) and DNAlytics. Advanced Therapy Medicinal Products (ATMPs) are among the most innovative and promising biomedicines designed to address unmet medical needs, including cell, gene, exosome and phage therapies.

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners (“Metalmark”), for the acquisition of its approximate 25% stake in Octomera LLC (“Octomera”), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027, along with a portion of the proceeds attributable to Octomera's cell processing services should there be a change of control in the next 10 years.

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

See News Rankings

Charts implemented using Lightweight Charts™